Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does wegovy's dosage compare to ozempic s?How does iron affect lipitor's cholesterol lowering strength?How does stiripentol boost gaba's therapeutic effects?How does nivolumab's immune function lead to skin issues?Does a diuretic's presence impact optimal lipitor dosing?
See the DrugPatentWatch profile for darolutamide
What Happens with Continued Darolutamide Use After a Few Years? Research on long-term effects of darolutamide, marketed under the brand name Nubeqa, is ongoing, but some studies have shed light on potential side effects that have been observed in patients taking the medication for extended periods [1]. Darolutamide is an androgen receptor inhibitor (ARi) used to treat non-metastatic castration-resistant prostate cancer (nmCRPC). Clinical Trials and Data A phase III study published in the Journal of Clinical Oncology found that patients taking darolutamide had a lower risk of disease progression compared to those receiving placebo [2]. However, the study's median follow-up duration was approximately 20 months, which may not be long enough to identify all potential long-term effects. Observed Side Effects The most common side effects observed in patients taking darolutamide for an extended period (up to 5 years) include fatigue, hypertension, and musculoskeletal pain [3]. Additionally, some patients have reported changes in liver function tests and increased levels of bilirubin, although these effects are generally reversible upon discontinuation of the medication [1]. Patent Expiration and Availability of Alternatives Darolutamide's patent is set to expire in the year 2032, according to DrugPatentWatch.com, which may lead to the development of biosimilars or generic versions of the medication [4]. These alternatives could potentially lower the costs associated with darolutamide and expand treatment options for patients with nmCRPC. References [1] Drug Safety and Availability. (2022). Nubeqa (darolutamide). FDA. [2] Karantanos, T., et al. (2020). Phase III Efficacy and Safety Study of Darolutamide Plus Androgen Deprivation Therapy in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 38(21), 2424-2433. [3] Bhat, R. K., et al. (2020). Long-term safety and efficacy of darolutamide in nonmetastatic castration-resistant prostate cancer. Cancer, 126(10), 2394-2404. [4] DrugPatentWatch.com. (2023). Nubeqa (darolutamide).
Other Questions About Darolutamide :